SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing presentation: reset
Once-Weekly Islatravir Plus Lenacapavir Maintains HIV-1 Suppression Through 96 Weeks: Phase II Study
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
1 of
1
|
Once-Weekly Islatravir Plus Lenacapavir Maintains HIV-1 Suppression Through 96 Weeks: Phase II Study (ABSTRACT
516)
Amy Colson
Community Resource Initiative, Boston, MA, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
1 of
1
|
